Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.

Cell cycle (Georgetown, Tex.) - 15 Mar 2008

Reuther Gary W

Abstract excerpt

The various roles and importance of JAK2 in cell signaling have been appreciated for some time. In 2005, a point mutation in JAK2 (JAK2-V617F) was identified in a number of neoplastic myeloproliferative disorders, ushering in a new era of JAK2 research. This discovery uncovered a new therapeutic target to treat these neoplasms and in turn possibly prevent their progression into cancer. A thorough understanding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to JAK2 gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Models, Biological

Share to Mutation

Share to Myeloproliferative Disorders

Share to Receptors, Cytokine

Share to Receptors, Interleukin

Source

Identifiers

PMID: 18245948
DOI: 10.4161/cc.7.6.5567

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.PMID 18245948Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.Semantic proximity Read ↗

Jak2: normal function and role in hematopoietic disorders.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted TherapiesSemantic proximity Read ↗

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overviewSemantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.Semantic proximity Read ↗

[Research advances in the role of JAK2 mutations in acute leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.